We think that the ACCC is uniquely positioned to bridge the gap between the needs in clinical trials and the patients who are in the community. Most clinical oncology is delivered in the community. That's where the patients are, that's where the need is, said Randall Oyer, MD, medical director of the Oncology Program at Penn Medicine Lancaster General Health and president of ACCC.
We think that the ACCC is uniquely positioned to bridge the gap between the needs in clinical trials and the patients who are in the community. Most clinical oncology is delivered in the community. That's where the patients are, that's where the need is, said Randall Oyer, MD, medical director of the Oncology Program at Penn Medicine Lancaster General Health and president of ACCC.
Transcript
Based off your 2021 ACCC presidential theme, can you discuss how vital increased data on patient response trends can prove when implementing new resources to promote clinical trials?
On an annual basis, the ACCC polls its members to find what their areas of interest are, what they see as the trends in the community, and what programs they'd like to build. In the 2019 trends survey, 1 in 4, almost 23% of our members told us that they're building expertise or partnering for clinical trials. I think that that's important.
ACCC members took part in a second survey that looked at the challenges in opening a clinical trials program or providing clinical trials in the community. Among the top responses were having enough resources, having enough trained personnel, and having patients who matched trial entry criteria and who were interested or who had been given the opportunity to have clinical trials.
Beyond our own surveys, there's other striking information in the community that points to the need for clinical trials in the community. There was a study that looked at open pancreas cancer trials across the country, 1 of our greatest needs: pancreas cancer. Only 15% of the spots were filled. In other words, there were open opportunities that went unfilled and many of those trials may not have been able to answer the question that they were originally designed to answer.
Additionally, we know that most community oncology programs have fewer than 10% of their patients on clinical trials. So, we think that the ACCC is uniquely positioned to bridge the gap between the needs in clinical trials and the patients who are in the community. Most clinical oncology is delivered in the community. That's where the patients are, that's where the need is. So, we think that the ACCC will be able to bridge that gap.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More